Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127086671 | 12708667 | 1 | I | 200209 | 20160822 | 20160901 | 20160901 | EXP | CN-VIIV HEALTHCARE LIMITED-CN2016GSK123597 | VIIV | LI C, PAN J, YANG A. ONE CASE OF NEWLY-ONSET LIVER CANCER AND DUAL DRUG-RESISTANCE DURING TREATMENT OF HEPATITIS B CIRRHOSIS WITH NUCLEOS(T)IDE ANALOGUES. CHINESE JOURNAL OF HEPATOLOGY. 2016;24 (3):228 | 60.00 | YR | M | Y | 0.00000 | 20160901 | OT | CN | CN |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127086671 | 12708667 | 1 | PS | LAMIVUDINE. | LAMIVUDINE | 1 | Oral | 100 MG, QD | Y | 21003 | 100 | MG | QD | ||||||
| 127086671 | 12708667 | 2 | SS | LAMIVUDINE. | LAMIVUDINE | 1 | Oral | 100 MG, UNK | Y | 21003 | 100 | MG | |||||||
| 127086671 | 12708667 | 3 | C | ADEFOVIR DIPIVOXIL. | ADEFOVIR DIPIVOXIL | 1 | 10 MG, UNK | 0 | 10 | MG | |||||||||
| 127086671 | 12708667 | 4 | C | ALBUMIN | ALBUMIN HUMAN | 1 | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 127086671 | 12708667 | 1 | Antiviral treatment |
| 127086671 | 12708667 | 3 | Antiviral treatment |
| 127086671 | 12708667 | 4 | Product used for unknown indication |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 127086671 | 12708667 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 127086671 | 12708667 | Drug resistance | |
| 127086671 | 12708667 | Gastric ulcer | |
| 127086671 | 12708667 | Gastrolithiasis | |
| 127086671 | 12708667 | Hepatic cancer | |
| 127086671 | 12708667 | Hepatitis B DNA increased | |
| 127086671 | 12708667 | Pathogen resistance | |
| 127086671 | 12708667 | Transaminases increased | |
| 127086671 | 12708667 | Upper gastrointestinal haemorrhage | |
| 127086671 | 12708667 | Viral mutation identified |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 127086671 | 12708667 | 2 | 2006 | 0 | ||
| 127086671 | 12708667 | 3 | 2006 | 0 |